In the revised 2016 World Health Organization classification of lymphoid neoplasms, Co-expression of c-MYC and BCL2 was considered as a new subgroup and defined as double-expressor lymphoma (DEL), which accounts for approximately one-third of DLBCL cases (5). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.